• **Name:** Maria Fernanda Mosele
• **Current Position & Affiliation:** Medical Oncologist at the Early Drug Department, Gustave Roussy Institut, Villejuif, France
• **Country:** France

• **Educational Background:** Fernanda Mosele received her MD from the Universidad of Buenos Aires in 2007, followed by specialized training in Clinical Oncology at the Universidad Católica Argentina. In 2018, Dr Mosele arrived in France, where she further advanced her expertise in precision medicine through postgraduate studies at Université Paris-Saclay.

• **Professional Experience:** Dr. Mosele worked as a medical oncologist in Buenos Aires and dedicated her expertise to patient care until 2018, when her passion for translational research led her to join the renowned Gustave Roussy in Villejuif, France. She initially collaborated with the breast cancer unit under the guidance of Professor Fabrice André, focusing on the prognosis and treatment outcomes of patients with metastatic breast cancer and *PIK3CA* mutations. Her commitment to precision medicine led to her collaboration with the ESMO Precision Medicine Working Group, contributing to the recommendations on the utilisation of next-generation sequencing (NGS) in the treatment of patients with metastatic cancer. Dr Mosele has developed extensive expertise in the mechanisms of action and resistance to antibody drug conjugates, establishing herself as one of the pioneers publishing in this evolving field. She currently works in the Department of Early Drug Development (DITEP), where she leads phase I–II clinical trials focused on targeted therapies for metastatic cancers. Additionally, she serves as the Medical Lead of the UNLOCK program, which investigates mechanisms of action and resistance of innovative drugs.

• **Professional Organizations:** Dr Mosele collaborates with the ESMO Precision Medicine Working Group since beginning of 2024 and she has active participation in different ESMO activities.

• **Main Scientific Publications:** Dr. Mosele played a pivotal role in formulating recommendations for the utilisation of next-generation sequencing (NGS) in the treatment of metastatic cancers, a seminal work published during 2020 and updated during 2024. Dr. Mosele also published a pioneering study in *Nature Medicine* as the lead author, unraveling the mechanisms of action and resistance to trastuzumab deruxtecan.